Drug intelligence / Profile preview

Polinorm-Forte

Development stage: Unknown
Lead developer: Ekomed
Modality: Small Molecules
Administration: Oral

Overview

Polinorm-Forte is a herbal phytoconcentrate developed by the Ukrainian company Ekomed in collaboration with the National Cancer Institute of Ukraine. It is formulated as a dietary supplement intended for supportive care in patients with various types of neoplasms. The product is a hydro-alcoholic extract of multiple medicinal plants, designed to provide immunomodulatory effects and support the body's detoxification processes during aggressive cancer treatments such as chemotherapy and radiation therapy. While it does not have a single defined molecular mechanism of action, it is used in integrative oncology to improve treatment tolerance, enhance systemic resistance, and improve the overall quality of life for patients.

Brand names: Polinorm-ForteПолінорм-Форте
Other names: Polinorm ForteПолінорм Форте

Beyond the preview

Go deeper on Polinorm-Forte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polinorm-Forte.

Explore the full profile